Advisory Research’s MacroGenics MGNX Stock Holding History

Advisory Research’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-21,112	Closed	-$672K	–	373
2021 Q1	$672K	Buy	+21,112	New	+$513K	0.05%	243

Other funds holding MGNX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Advisory Research's MGNX Position: Q2 2021 in Review

Advisory Research sold out of MacroGenics (MGNX) in Q2 2021, closing a stake of 21,112 shares — an estimated $672K sold.

Advisory Research first reported a position in MGNX in Q1 2021 and held it in 1 quarter. The position peaked at $672K in Q1 2021. 149 funds tracked by Wall St. Rank hold MGNX as of Q2 2021.

Advisory Research reported no remaining MacroGenics position as of Q2 2021 after selling out during the quarter.
Advisory Research sold 21,112 MacroGenics shares in Q2 2021, an estimated $672K.
Advisory Research first reported a position in MacroGenics in Q1 2021 and held it in 1 quarter.
Advisory Research's MacroGenics position peaked at $672K in Q1 2021.
149 funds tracked by Wall St. Rank held MacroGenics as of Q2 2021.

Based on Advisory Research's 13F filing for Q2 2021, filed 16 Aug 2021.